Clozapine for schizophrenia. Clinical effect, financial considerations, and quality requirements

Nordic Journal of Psychiatry

Volumn 54, Issue 2, 2000, Pages 143-148

  Erlandsen, Christian ^a  

^a NONE

Author keywords

Clozapine; Cost effectiveness; Long term; Schizophrenia

Indexed keywords

CLOZAPINE;

AGRANULOCYTOSIS; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DROWSINESS; EXTRAPYRAMIDAL SYNDROME; HOSPITALIZATION; HUMAN; HYPERSALIVATION; LEUKOPENIA; MAJOR CLINICAL STUDY; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 0034083189     PISSN: 08039488     EISSN: None     Source Type: Journal    
DOI: 10.1080/080394800427447     Document Type: Article

References (24)

1. The ICD-10. Classification of mental and behavioral disorders. Geneva: World Health Organization: 1992. p. 86.
2. Erlandsen C. Utproving av et nytt nevroleptikum, Leponex (clozapin) hos schizofrene med lang sykehistorie. Nord J Psychiatry 1981;3:248-53.
3. Bakken K, Bratli T, Erlandsen C, Lingjærde O, Nome S. Local monitoring center for clozapine therapy: quality assurance of drug treatment in a group of psychiatric patients. Tidsskr Nor Laegeforen 1998;7:1076-8.
4. Løvdahl H. Skåring av pasienttilstand GAF. Oslo: Department for Clinical Psychiatric Research, Ullevål Hospital. Internett address: http//www//transmit.no/gaf/.
5. Andreasen NC, Noppulos P, Schultz S, Miller D, Gupata S, Swayze V, et al. Positive and negative symptoms of schizophrenia. Acta Psychiatr Scand 1994;90 Suppl 384:51-9.
6. Gerlach J. Extrapyramidal side effects. Nord J Psychiatry 1997;51 Suppl 40:25-9.
7. Gerlach J. Clozapine side effects. Nord J Psychiatry 1997;51 Suppl 40:65-8.
8. Rabinowitz T, Frankenburd FR, Kando J. The effect of clozapine on saliva flow rate: A pilot study. Biol Psychiatry 1996;40:1132-4.
9. Norwegian Central Bureau of Statistics. Dodsårsaker, 1999, main tables. Oslo: Statistisk Sentralbyrå; 1995.
10. Verghese C, DeLeon J, Nair C, Simpson GM. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry 1996;39:135-8.
11. Fleischacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatr Scand 1994;89 Suppl 382:11-5.
12. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-rasistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-90.
13. Nordby K, Wold S. Underveis. Stange, Norway: Hedmark County, Sanderud Hospital in co-operation with the High School in Hedmark, Department of Nursing.
14. Andrew M. Legemidler og kvalitetssikring i sykehus - et ansvar også for legene. Tidsskr Nor Laegeforen 1992;112:1877-80.
15. Nylenna M. Gode journaler er god medisin. Tidsskr Nor Laegeforen 1992;112:3560-4.
16. Ruud J. Men hjemme best. Langtidspsykiatriske pasienter i en kommunal omsorgs-og behandlingsmodell 1996. Oslo: Lægeforeningens kvalitetssikringsfond; 1996.
17. Fitton A, Benfield P. Clozapine. An appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. Pharmaeconomics 1993;4:131-56.
18. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993;162:38-42.
19. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:163-6.
20. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with Clozapine. Hosp Community Psychiatry 1994;45:261-4.
21. Lindstrom LH. The effect of long-term treatment with clozapine in schizophrenia for up to 13 years. Acta Psychiatr Scand 1988;524-9.
22. Grund J, Husbyn H. Økonomisk evaluering av legemidler. Oslo: Universitetsforlaget; 1993. p. 239-50.
23. Lundberg T. Clozapine - an atypical nevroleptic. A pharmacokinetic, PET and clinical study. Uppsala Sweden: Uppsala University; 1995.
24. Lingjærde O, Bela M, Kruger MB, Dahle LG, Fossheim I, Helle J, et al. Improvement patterns in schizophrenic 'non-responders' treated with clozapine. A systematic study over 1 year. Nord J Psychiatry 1996;50:457-67.